Immune intelligence startup Serimune hopes to better understand the association between antibody epitopes (parts of antigen molecules that bind to antibodies) and SARS-CoV-2 viruses.
The company’s proprietary technology, originally developed at UC Santa Barbara, provides a new and distinctive way of mapping a person’s entire array of antibodies through a small blood sample. They do this through the use of a bacterial peptide display – a type of screening mechanism that can separate plasmid DNA from antibody-bound DNA in a sample. This DNA can then be sequenced to identify epitopes, both of which provide information about which antigens one may come into contact with, as well as how his or her immune system responded to them.
“UC San Diego has a degree in molecular biology and has previously worked for several diagnostics companies,” said Noah Nassar, CEO of Serimune.
This week, Serumune Announced the launch of a new application of its core technology Helps to understand disease status and immune response to SARS-CoV-2, or the virus that causes COVID-19.
“So what we do is we create these antibody profiles, and then we map to the SARS-COV-2 proteome with about 12 amino acid specificities,” Nasir said. “And we find that antibody expression is highly related to disease status, so we can differentiate mild, moderate, severe, and asymptomatic disease based on the antibodies present in the sample.”
The more patient data Serumune can gather, the better its basic technology is able to find different antigen exposures and patterns of disease severity. Notifying those patterns soon will not only help clinicians and researchers understand how the SARS-CoV-2 virus operates, but also inform new approaches to diagnosis, treatment, and vaccines for any antigen. Can.
Ceremune’s introduction of its new COVID antibody epitope mapping service is a way to make this data more accessible to customers such as vaccine companies, government agencies, and academic laboratories that have demonstrated an interest in better understanding the immune response to SARS-CoV-2 is.
“This information had to be zeroed out, which the researchers wanted to know and standardize,” said Nasser. “We can actually provide these results back in two days from the sample receipt.”
Beyond this new service, Sirimune also plans to launch Longitudinal clinical studies on immunity to SARS-CoV-2. Using a painless at home collection kit, study participants send small blood samples to serimune, which then uses its main technique to outline an individual immune map.
“We offer COVID their results as an individual immune scenario,” Nasser said. “And what we’re trying to do is to understand how the immune response changes over time, and what happens to that immune response when exposed to COIDID.”
The mapping technique has become so specialized now that it can tell whether a patient has antibodies to natural exposure ranging from SARS-CoV-2 virus or a vaccine.
While the primary focus for Serimune remains these applications for the COVID-19 pandemic for now, Nasser also noted that the company plans to move into personalized medicine, potentially serving its mapping services directly to aspiring patients Offered.
“We believe it is of value to individual patients to understand their immune status and which antigens they have been exposed to,” he said. Until then, Serimmune plans to continue its database with more patient samples.